GSK will acquire the liver disease drug efimosfermin from Boston Pharmaceuticals in a deal worth up to $2 billion, The Wall Street Journal reported May 14.
The agreement includes a $1.2 billion upfront payment along with an additional $800 million tied to future development and regulatory agreements.
As part of the deal, GSK will acquire Boston Pharmaceuticals’ subsidiary BP Asset IX to gain full rights to the drug. Efimosfermin, aimed at treating steatotic liver disease, is in late-stage trials and could reach the market by 2029.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
